EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors

Naglaa M Ahmed, Rizk E Khidre, Mohamed R Khidre, Ahmed El-Morsy, Tamer Nasr, Khaled El-Adl, Noura S Hanafy

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Naglaa M Ahmed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents, Protein Kinase Inhibitors, Thiazoles. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we highlight the synthesis of a number of novel pyridine/thiazole hybrids 1 to 6a,b and their screening as possible anticancer drugs through dual targeting of VEGFR-2 and EGFR. The novel compounds were created in accordance with the structural specifications of the target receptors. The MTT assay was used to assess the compounds' cytotoxicity against the cancer cell lines HepG2, MCF-7, HCT116, and A549. With IC50 values of 6.50, 7.00, 5.55, and 6.85 μM against HepG2, MCF-7, A549, and HCT116 cell lines, respectively, compound 5b demonstrated the strongest anticancer activity. Although it was less effective than sorafenib against the studied cell lines, it was more effective than erlotinib against HepG2, MCF-7, and HCT116, while it was less effective against A549. The six potent compounds 4a, 4b, 4c, 5a, 5b, 6a, and 6b were assessed for their toxic effects on VERO normal cell lines to determine cytotoxicity levels. Results across all studies indicated that every synthesized compound demonstrated minimal toxicity toward VERO normal cells, with IC50 values ranging between 47.60 and 52.22 μM. Additionally, molecular modeling studies were used to investigate how well the novel derivatives could interact with EGFR and VEGFR-2 receptors. Furthermore, the compounds underwent additional testing to measure their capacity to inhibit both EGFRT790M and VEGFR-2. Compounds 5b, 4b, 4c, and 6b demonstrated excellent inhibitory potency against VEGFR-2, exhibiting IC50 values of 0.95, 1.00, 1.15, and 1.35 μM, respectively. Also, compounds 5b, 4c, 4b, and 6b inhibited EGFRWT activity with IC50 = 0.24, 0.30, 0.37 and 0.40 μM respectively. Similarly, these same compounds displayed superior inhibitory effects on EGFRT790M, with corresponding IC50 values of 0.26, 0.36, 0.44, and 0.50 μM, respectively. Notably, derivatives 5b, 4b, and 4c exhibited good in silico ADMET predictions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsProtein Kinase InhibitorsThiazolesMolecular Docking SimulationPyridinesDrug DesignHumansErbB ReceptorsDrug Screening Assays, AntitumorStructure-Activity RelationshipMolecular StructureCell ProliferationDose-Response Relationship, DrugAnimalsCell Line, TumorChlorocebus aethiops

Stichwörter der Autor:innen

ADMETAnticancerPyridineThiazoleTyrosine kinase

Substanzen

ErbB ReceptorsVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsProtein Kinase InhibitorsThiazolesPyridinesKDR protein, humanEGFR protein, humanpyridine

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Cairo 11795, Egypt.
  • Chemical Industry Research Institute, National Research Centre (NRC), 12622, Dokki, Giza, Egypt.
  • Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Pharmaceutical Chemistry Department, College of Pharmacy, The Islamic University, Najaf, Iraq.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Egypt-Japan University of Science and Technology (E-JUST), P.O. 21934 Alexandria, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Capital Universi…
  • Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11884 Cairo, Egypt; Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustain…

Zitieren

APA

Ahmed, N. M., Khidre, R. E., Khidre, M. R., El-Morsy, A., Nasr, T., El-Adl, K., & Hanafy, N. S. (2026). Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110460

Vancouver

Ahmed NM, Khidre RE, Khidre MR, El-Morsy A, Nasr T, El-Adl K, et al. Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110460

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Naglaa M and Khidre, Rizk E and Khidre, Mohamed R and El-Morsy, Ahmed and Nasr, Tamer and El-Adl, Khaled and Hanafy, Noura S},
  title = {Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110460}
}
Kostenlos starten →